問卷

TPIDB > Search Result

Search Result

篩選

List

5Cases

2025-03-01 - 2030-06-30

Active
A phase III, randomized, double-blind, placebo-controlled, event-driven trial was conducted to evaluate the effect of Baxdrostat in combination with Dapagliflozin compared to Dapagliflozin alone on the risk of first-time heart failure and cardiovascular death in participants at high risk of developing heart failure.
  • Condition/Disease

    The time elapsed before the first occurrence of any of the following events: • Hospitalization due to HF • Non-hospitalized HF • Death due to CV

  • Test Drug

    Baxdrostat Dapagliflozin

Participate Sites
18Sites

Recruiting18Sites

2025-07-01 - 2030-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
23Sites

Recruiting23Sites

2026-06-01 - 2030-06-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2024-03-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
20Sites

Not yet recruiting11Sites

Recruiting8Sites

2021-09-01 - 2022-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting10Sites

Terminated2Sites